Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPHAJJAR, Ludhmila AbrahaoFONSECA, Silvia Moulin RibeiroMACHADO, Theuran Inahja Vicente2022-04-192022-04-192021FRONTIERS IN CARDIOVASCULAR MEDICINE, v.8, article ID 590768, 5p, 20212297-055Xhttps://observatorio.fm.usp.br/handle/OPI/45897Cancer patients have a higher risk of atrial fibrillation (AF) than general population, the pathophysiology mechanisms involves the pro inflammatory status of immune system in these patients and the exacerbated inflammatory response to cancer treatment and surgeries. Adequate management and prophylaxis for its occurrence are important and reduce morbidity and mortality in this population. There is a challenge in AF related to cancer to predict thromboembolic and bleeding risk in these patients, once standard stroke and hemorrhagic prediction scores are not validated for them. It is used CHA2DS2-VASc and HAS-BLED scores, the same as used in general population. In this review, we demonstrate correlated mechanisms to occurrence AF in cancer patients as well as therapeutic challenges in this population.engopenAccessatrial fibrillationcanceranticoagulationcardiotoxicitydrug-drug interactionanticoagulationtherapyarticleCopyright FRONTIERS MEDIA SA10.3389/fcvm.2021.590768Cardiac & Cardiovascular Systems